{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pillai V"],"funding":["NCI NIH HHS"],"pagination":["3539-3549"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6880911"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(22)"],"pubmed_abstract":["Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level, on leukemic blasts, the presence of CD19- subpopulations, and especially prior CD19-targeted therapy, on the response to CAR T-cell therapy has not been determined. We analyzed 166 patients treated with CAR T-cell therapy at our institution. Eleven patients did not achieve a minimal residual disease (MRD)- deep remission, whereas 67 patients had a recurrence after achieving a MRD- deep remission: 28 patients with CD19+ leukemia and 39 patients with CD19- leukemia. Return of CD19+ leukemia was associated with loss of CAR T-cell function, whereas CD19- le"],"journal":["Blood advances"],"pubmed_title":["CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy."],"pmcid":["PMC6880911"],"funding_grant_id":["P30 CA016520","P01 CA214278","U01 CA232563"],"pubmed_authors":["Pillai V","Muralidharan K","Cherian S","Oldridge DA","Mohan D","Rheingold SR","Melenhorst JJ","Meng W","Bhoj VG","DiNofia AM","Fromm JR","Paessler M","June CH","Thomas-Tikhonenko A","Luo M","Van Arnam J","Bagashev A","Grupp SA","Maude SL","Rosenthal J","Luning Prak ET","Wertheim G"],"additional_accession":[]},"is_claimable":false,"name":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.","description":"Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level, on leukemic blasts, the presence of CD19- subpopulations, and especially prior CD19-targeted therapy, on the response to CAR T-cell therapy has not been determined. We analyzed 166 patients treated with CAR T-cell therapy at our institution. Eleven patients did not achieve a minimal residual disease (MRD)- deep remission, whereas 67 patients had a recurrence after achieving a MRD- deep remission: 28 patients with CD19+ leukemia and 39 patients with CD19- leukemia. Return of CD19+ leukemia was associated with loss of CAR T-cell function, whereas CD19- le","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-21T15:51:46.923Z","creation":"2020-05-21T19:45:24Z"},"accession":"S-EPMC6880911","cross_references":{"pubmed":["31738832"],"doi":["10.1182/bloodadvances.2019000692"]}}